Health and population

Elsevier,

Seminars in Oncology Nursing, Volume 34, Issue 1, February 2018, Pages 52-59.

Contributing to SDG 3 (good health and well-being) and SDG 10 (reduced inequalities), this article discusses integrating sexual and gender minority identities with cancer survivor identities and the coordination of medical care.
Elsevier,

The Lancet, Volume 391, Issue 10119, 1 February 2018, Page 401

In support of SDG 5, this article argues that to eliminate female genital mutilation (FGM) worldwide by 2030, national legislation alone is insufficient and must be accompanied by concerted efforts to change deeply embedded cultural attitudes in communities that continue to perpetuate FGM.
The Lancet Report - Stillbirth in low and middle-income countries
Highlighting the data behind stillbirths to bring about change, this article and video supports SDG 3. 2.6 million babies worldwide are stillborn each year. The majority of these are preventable. The Lancet partnered with the London School of Hygiene & Tropical Medicine to find solutions to end this silent scandal.
This study performed a retrospective study on the hormonal and metabolic effects of cross-sex hormone therapy (CSHT) in a small cohort of transgender patients. Research findings contribute to SDG 3 (good health and well-being) and SDG 10 (reduced inequalities).
This report seeks to provide an in-depth review of SDG 6 and includes data on the global baseline status, the current situation and trends at global and regional levels, and what more needs to be done to achieve this goal by 2030. The report is based on the latest data available for the 11 SDG 6 global indicators selected by Member States to track progress towards the eight global targets, plus complementary data and evidence from a wide range of sources.
SDG 3.3 sets a target of combating viral hepatitis. Sub-Saharan Africa carries a substantial portion of the global burden of viral hepatitis. Countries in the region face unique challenges, with the development of elimination strategies often hindered by a lack of good quality data. This paper outlines the current status of hepatitis C in sub-Saharan Africa and provides expert recommendations from across the region, including simplified diagnostic and treatment algorithms for use in low-resource settings.
Three or more cups of coffee daily halves mortality risk in patients with both HIV and HCV. This finding is based on a large nation-wide study in France. This is relevant to SDG 3 and specifically the targets concerned with the reduction of infection diseases, like hepatitis C (HCV).
SDG 3.3 sets a target of combating viral hepatitis. Sub-Saharan Africa carries a substantial portion of the global burden of viral hepatitis. Countries in the region face unique challenges, with the development of elimination strategies often hindered by a lack of good quality data. This paper outlines the current status of hepatitis B in sub-Saharan Africa and provides expert recommendations from across the region, including simplified diagnostic and treatment algorithms for use in low-resource settings.
HIV Rapid Test being administered (Equality Michigan viaWikimedia Commons)
Patients in China can face long delays in completing their testing and initiating treatment when newly diagnosed with HIV. This study aimed to improve linkage to care by assessing the effectiveness of an intervention involving rapid point-of-care testing, trialled in Guangxi Zhuang Autonomous Region, south China. The intervention increased the number of patients starting treatment and reduced mortality. However, difficulties in ensuring patients remained in the care cascade were noted and highlights the challenges China faces in meeting the SDG 3 goals.
Elsevier,

Lancet Oncology Commission, November 2017

Lancet Oncology commission report
The report is authored by over 50 leading oncologists, including members of leading US cancer organizations, and sets out 13 key priority areas, each with measurable goals, to focus the $2 billion of funding released to the National Cancer Institute (NCI) as part of the 21st Century Cures Act. The report sets out a detailed road map to deliver on the Blue Ribbon Panel recommendations, including a focus on prevention, a new model for drug discovery and development, a vast expansion of patient access to clinical trials, and an emphasis on targeted interventions to improve cancer care for underserved groups, specifically children, cancer survivors and minority groups.

Pages